Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06331312 · ClinicalTrials.gov registry record · Phase 3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
A Phase 3 study of Polymyalgia Rheumatica, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 20
- Study locations
NCT06331312 is a Phase 3 study of Polymyalgia Rheumatica that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 288 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06331312, a Phase 3 study of Polymyalgia Rheumatica, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Conditions Studied
Interventions
- BIOLOGICAL Secukinumab
Study Locations (20)
Florida
- Rheumatology Associates of South Florida - Boca Raton
- UF Health Cancer Center - Gainesville
- Sarasota Arthritis Res Ctr - Sarasota
- West Broward Rheumatology Associates Inc - Tamarac
California
- Orrin Troum MD and Medical Associates - Santa Monica
- Center for Rheumatology Research - West Hills
- Millennium Clinical Trials - Westlake Village
Texas
- Prolato Clinical Research Center - Houston
- Accurate Clinical Research Inc - San Antonio
- Advanced Rheumatology of Houston - Spring
Arizona
- Arizona Arthritis and Rheumatology Associates PLLC - Avondale
- Sun Valley Arthritis Center Ltd - Peoria
Georgia
- Arthritis Center of North Georgia - Gainesville
Maryland
- Klein and Associates - Hagerstown
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Clinical Research Inst of MI - Saint Clair Shores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2028-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06331312
The ClinicalTrials.gov registry entry for NCT06331312 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 288 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Polymyalgia Rheumatica appearing as the primary indexed condition, and to 1 intervention - of which Secukinumab is the first listed.
NCT06331312 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06331312 about?
NCT06331312 is a clinical study titled "Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)". The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
What is the current status of trial NCT06331312?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2024-06-28. Estimated completion is 2028-08-22.
What conditions does trial NCT06331312 study?
This clinical trial studies the following conditions: Polymyalgia Rheumatica.
What interventions are being tested in trial NCT06331312?
The interventions under investigation include: Secukinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06331312?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06331312 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polymyalgia Rheumatica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.